Cognizant Technology Solution   Report issue

For profit Phase 1 Phase 3
Founded: Teaneck NJ United States (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2017
NCT03162055
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

formoterol (foradil) (1 trial)

glycopyrronium (robinul) (1 trial)

Drugs in Phase 1 Trials (1)

Key: Cognizant Technology Solution (0) Acquired (1)

fingolimod (gilenya) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3